FY2024 Earnings Forecast for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Leerink Partnrs dropped their FY2024 earnings per share estimates for IQVIA in a research report issued to clients and investors on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $10.07 per share for the year, down from their previous estimate of $10.15. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2025 earnings at $10.91 EPS.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Performance

NYSE:IQV opened at $197.57 on Wednesday. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a fifty day simple moving average of $223.40 and a two-hundred day simple moving average of $227.35. The company has a market capitalization of $35.86 billion, a P/E ratio of 25.93, a P/E/G ratio of 1.97 and a beta of 1.51.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Large investors have recently added to or reduced their stakes in the stock. Covestor Ltd grew its stake in IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the period. O Shaughnessy Asset Management LLC grew its position in shares of IQVIA by 25.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 7,501 shares of the medical research company’s stock worth $1,897,000 after buying an additional 1,513 shares during the period. Lake Street Advisors Group LLC bought a new position in shares of IQVIA in the 1st quarter worth about $339,000. CANADA LIFE ASSURANCE Co lifted its position in IQVIA by 5.0% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 157,380 shares of the medical research company’s stock valued at $39,807,000 after acquiring an additional 7,544 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its holdings in IQVIA by 213.8% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,929 shares of the medical research company’s stock worth $994,000 after purchasing an additional 2,677 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.